MorphoSys: A European Champion Crossing The Biopharma Rubicon
Insight Into Europe's Maturing Biopharma Market
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
You may also be interested in...
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.